科室简介
北京大学第三医院（北医三院）始建于1958年，是国家卫生健康委委管医院，是集医疗、教学、科研、预防保健、康复与健康管理为一体的综合性三甲医院。多年以来，北医三院医疗服务量和效率始终居于北京市前列，连续六年获得全国三级公立医院绩效考核A++。2022年，北医三院入选全国14家公立医院高质量发展试点医院。北医三院拥有中国科学院院士1人、中国工程院院士2人，国家自然科学基金杰出青年基金获得者8人，长江学者4人，国家高层次人才特殊支持计划科技创新领军人才2人。
北医三院于1999年成立风湿病专业组，2000年1月正式开设风湿免疫病门诊，2006年正式成立风湿免疫科。经过近20年的发展，学科在北京市及国内的影响力不断攀升，是国家骨科与运动康复临床医学研究中心脊柱关节炎一体化诊疗项目示范单位。近年来在中国医院科技影响力（STEM）风湿病学与自体免疫病学领域排名处于前20。
目前科室床位30张，年门诊量7万人次，年住院患者1600余人次。在职医护人员28人，其中教授、副教授2人，主任医师3人、副主任医师4人、副研究员1人、副主任护师1人。研究生导师3人。科室开展了CAR-T细胞治疗难治性风湿病、富血小板血浆治疗严重骨关节炎、肉毒素注射改善顽固性雷诺及肢端溃疡、关节超声引导下微创治疗等多个特色诊疗项目。科室开设了专病门诊、医药联合门诊、夜间特需门诊、周末门诊，以及互联网云门诊，为患者提供全方位的诊疗服务。2024年获得“北京大学第三医院优秀服务先进集体一等奖”。科室护理团队与临床、科研协同发展，在风湿病管理及危重症患者管理方面积攒了丰富的经验。
科室是北京大学博士及硕士学位授权点，风湿免疫病专科医师培训基地。多人获得北京大学医学部优秀教师奖和北京大学第三医院优秀教师奖。共培养研究生30余人。培养来自全国各地进修医师近百名，包括部分地区风湿学科带头人、高级职称专家。
科室作为全国重点实验室和国家自然科学基金基础科学中心骨干单位，先后承担国家自然科学基金课题13项，北京市自然科学基金2项，科技部国家重点研发计划1项，北京市卫健委卓越研究计划1项，中国博士后科学基金1项。科室成员在Nature、Cell、Immunity、Cell Stem Cell、Nature Reviews Rheumatology等高水平期刊发表相关研究成果。主编、副主编《图表式临床风湿病学》、《风湿免疫科疑难罕见病病例精解》、《风湿免疫病学》等多部风湿病教材及专著，在国际重要学术会议上报告数十次。我科也是较早获批的国家临床药理实验基地，可承接I-IV期临床药物试验，近5年承担国际、国内多中心药物临床试验40余项，牵头“评价YL-90148片在痛风患者中的有效性、安全性和药代动力学的多中心、随机、开放的临床试验”、“一项在类风湿关节炎（RA）参与者中评估PIT565的安全性、耐受性和药代动力学的Ib期、开放标签、剂量递增研究”等多项I期临床试验项目。学科带头人穆荣教授担任亚太抗风湿联盟（APLAR）教育委员会主席，具有较高的学术影响力。
科室始终坚持公立医院公益性，以“国家队”的责任担当护佑人民生命健康。从雪域高原到抗疫前线，科室以实际行动书写医者大爱。科室多名医护人员参与援鄂抗疫国家医疗队、驰援拉萨疫情，持续开展援藏、援疆、巡回医疗、医疗帮扶：参加医疗人才“组团式”援藏，在雪域高原接力帮扶当地医疗卫生事业发展；赴疆扎实推进援疆工作。
在科主任穆荣教授的带领下，秉持着严谨治学的态度，一切以“病人为中心”，对技术精益求精，全科工作人员不断提高风湿免疫疾病的临床诊治水平，救治大量疑难危重患者。北医三院风湿免疫科一直秉承着“仁心仁术，莫善于诚”的态度一路向前，用近20年的时间，砥砺前行，不骄不躁、潜心研究，为患者送上康复的机会，为风湿病学科发展贡献自己的力量。未来，机遇与挑战并存，压力与动力同在，北医三院风湿免疫科将继续不忘初心、牢记使命，赢得新的成绩，续写新的篇章。
（北京大学第三医院 魏慧 穆荣）
Peking University Third Hospital (Beiyi San Yuan) was established in 1958 and is a national tertiary-A general hospital directly under the National Health Commission, integrating medical care, teaching, research, preventive healthcare, rehabilitation, and health management. Over the years, the hospital has consistently ranked among the top in Beijing in terms of medical service volume and efficiency, receiving an A++ rating in the national performance evaluation of public tertiary hospitals for six consecutive years. In 2022, it was selected as one of China's 14 pilot hospitals for high-quality development of public hospitals.
The hospital boasts 1 academician of the Chinese Academy of Sciences, 2 academicians of the Chinese Academy of Engineering, 8 recipients of the National Science Fund for Distinguished Young Scholars, 4 Changjiang Scholars, and 2 leading scientific and technological innovation talents under the National High-Level Talent Special Support Program.
The Rheumatology specialty group was established in 1999, with the Rheumatology and Immunology Clinic officially opening in January 2000. The Department of Rheumatology and Immunology was formally established in 2006. Over nearly two decades of development, the department has grown in influence both in Beijing and nationwide. It serves as a demonstration unit for the integrated diagnosis and treatment of spondyloarthritis under the National Clinical Research Center for Orthopedics and Sports Rehabilitation. In recent years, it has ranked among the top 20 in China in the Science and Technology Evaluation Metrics (STEM) for rheumatology and autoimmune diseases.
Currently, the department has 30 inpatient beds, with an annual outpatient volume of 70,000 visits and over 1,600 hospitalizations. The team consists of 28 medical staff, including 2 professors/associate professors, 3 chief physicians, 4 deputy chief physicians, 1 associate researcher, and 1 deputy chief nurse. There are also 3 postgraduate supervisors.
The department offers several specialized diagnostic and treatment programs, including:
CAR-T cell therapy for refractory rheumatic diseases
Platelet-rich plasma (PRP) therapy for severe osteoarthritis
Botulinum toxin injections for refractory Raynaud’s phenomenon and digital ulcers
Minimally invasive treatments under ultrasound guidance
To provide comprehensive care, the department has established specialty clinics, combined medical-pharmacy clinics, evening VIP clinics, weekend clinics, and online "cloud" consultations. In 2024, it was awarded the "First Prize for Outstanding Service" at Peking University Third Hospital. The nursing team collaborates closely with clinical and research efforts, accumulating extensive experience in rheumatic disease management and critical care.
The department is an authorized doctoral and master's training site at Peking University and serves as a rheumatology specialist training base. Many faculty members have received "Outstanding Teacher" awards from Peking University Health Science Center and Peking University Third Hospital. Over 30 postgraduate students have been trained, along with nearly 100 visiting physicians from across China, including some who have become department heads and senior experts in rheumatology.
As a key unit of the National Key Laboratory and the National Natural Science Foundation of China (NSFC) Basic Science Center, the department has undertaken:
13 NSFC projects
2 Beijing Natural Science Foundation projects
1 National Key R&D Program
1 Beijing Municipal Health Commission Outstanding Research Program
1 China Postdoctoral Science Fund project
Research findings have been published in top-tier journals such as Nature, Cell, Immunity, Cell Stem Cell, and Nature Reviews Rheumatology. The department has also edited or co-edited several rheumatology textbooks and monographs, including:
Chart-Based Clinical Rheumatology
Case Studies of Rare and Complex Rheumatic Diseases
Rheumatology and Immunology
Additionally, the department is an early-approved national clinical pharmacology trial base, conducting Phase I-IV clinical trials. Over the past five years, it has participated in over 40 international and domestic multicenter drug trials, leading several Phase I trials, such as:
"A multicenter, randomized, open-label trial evaluating the efficacy, safety, and pharmacokinetics of YL-90148 in gout patients"
"An Ib phase, open-label, dose-escalation study assessing the safety, tolerability, and pharmacokinetics of PIT565 in rheumatoid arthritis (RA) patients"
Professor Mu Rong, the department director, serves as the Chair of the Education Committee of the Asia-Pacific League of Associations for Rheumatology (APLAR), demonstrating significant academic influence.
Upholding the public welfare mission of public hospitals, the department has demonstrated the responsibility of a "national team" in safeguarding public health. From the Tibetan Plateau to the frontlines of pandemic response, the team has exemplified medical dedication. Many staff members have participated in:
National medical teams aiding Hubei during COVID-19
Emergency support for Lhasa during outbreaks
Long-term medical aid programs in Tibet and Xinjiang
Mobile medical services and healthcare assistance initiatives
Under the leadership of Professor Mu Rong, the department adheres to a rigorous academic approach, prioritizing patient-centered care and technical excellence. The team continuously improves clinical diagnosis and treatment capabilities, saving numerous patients with complex and critical conditions.
For nearly 20 years, the Department of Rheumatology and Immunology at Peking University Third Hospital has upheld the principle of "benevolence and sincerity", advancing with humility and dedication. It has provided hope for recovery to countless patients while contributing to the development of rheumatology.
Moving forward, amid opportunities and challenges, the department remains committed to its original aspirations and mission, striving for new achievements and writing the next chapter in its story.
(By Wei Hui & Mu Rong, Peking University Third Hospital)
Copyright © 2022 北京大学第三医院 京ICP备05082115号-2
